SAN CARLOS, Calif.--(BUSINESS WIRE)--Sept. 6, 2006--NeurogesX, Inc., a privately held specialty pharmaceutical company, presented results from an open-label 40-week extension study in painful HIV-associated neuropathy (HIV-AN) patients that indicated repeat treatment with Transacin(TM) (NGX-4010) resulted in consistent reductions in pain over the entire 52-week study period. The magnitude of response to the open-label Transacin treatments was comparable to the response observed during the 12-week controlled portion of the study. Long-term use of Transacin was well tolerated without evidence of cumulative toxicity. NeurogesX has initiated a confirmatory pivotal Phase 3 multi-center, randomized, double-blind, controlled study with Transacin in 480 patients with HIV-AN.
